UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045638
Receipt number R000052032
Scientific Title Validation of effects by taking a single dose of test food, on brain waves and autonomic nervous system
Date of disclosure of the study information 2022/10/05
Last modified on 2022/10/05 14:41:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation of effects by taking a single dose of test food, on brain waves and autonomic nervous system

Acronym

Validation of effects by taking a single dose of test food, on brain waves and autonomic nervous system

Scientific Title

Validation of effects by taking a single dose of test food, on brain waves and autonomic nervous system

Scientific Title:Acronym

Validation of effects by taking a single dose of test food, on brain waves and autonomic nervous system

Region

Japan


Condition

Condition

Healthy male/female adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to verify some kind of effect on brain waves and the autonomic nervous system, by the test-food intake in a single dose

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Brain waves

Key secondary outcomes

1. Heartbeat
2. Cerebral stress
3. Cerebral fatigue
4. Psychological questionnaire
5. Flavor-evaluating questionnaire
6. Subjective vitality scale (Japanese ver.)


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Consumption of the test liquid (200 mL) to the subjects within 5 min.

Interventions/Control_2

Consumption of the placebo liquid (200 mL) to the subjects within 5 min.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

35 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Male/female subjects ranging in age from 20 to 34 at informed consent.
(2) Subjects having less than 25.0 kg/m2 of BMI.
(3) Subjects with no smoking (not less than one year).
(4) Subjects who can give informed consent to participate in this study, after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) Subjects being under some kind of continuous medical treatment, including the test period.
(2) Subjects who have periodically used health-specific / functional / health foods including supplements, which might affect the autonomic nervous system, metabolism and sleep.
(3) Subjects with incompatible chest (e.g., thick bodyhair, pacemaker-fitting) for heartbeat measurements.
(4) Subjects with excessive alcohol intake (not less than 60 g/day/week).
(5) Subjects with extremely irregular eating habits, and subjects having an irregular life rhythm with irregular shift work or midnight one.
(6) At the moment of informed consent, subjects who are under the other clinical tests with some kind of medicine/food, or participated in those within four weeks after the current trial, or are planning to join those after the consent.
(7) Subjects who are under a large stress condition with some kind of life event, such as house-moving, transfer, bereavement, etc., within three months before the agreement for this trial and during the test period.
(8) Subjects with any difficulty in giving up drinking since the day before the scheduled date of this trial.
(9) Subjects with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs.
(10) Subjects getting excessive exercise every day.
(11) Subjects with a serious symptom of premenstrual syndrome.
(12) Pregnant, possibly pregnant, and lactating women.
(13) Subjects having some kind of drug and/or food allergy.
(14) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.

Target sample size

27


Research contact person

Name of lead principal investigator

1st name Fumiko
Middle name
Last name Nakamura

Organization

CPCC Company Limited

Division name

Clinical Support Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Email

cpcc-contact@cpcc.co.jp


Public contact

Name of contact person

1st name Masanori
Middle name
Last name Numa

Organization

CPCC Company Limited

Division name

Clinical Planning Department

Zip code

101-0047

Address

4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

TEL

03-5297-3112

Homepage URL


Email

cpcc-contact@cpcc.co.jp


Sponsor or person

Institute

CPCC Company Limited

Institute

Department

Personal name



Funding Source

Organization

Asahi Quality & Innovations, Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 10 Month 05 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 09 Month 21 Day

Date of IRB

2021 Year 09 Month 17 Day

Anticipated trial start date

2021 Year 10 Month 06 Day

Last follow-up date

2021 Year 11 Month 26 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 10 Month 01 Day

Last modified on

2022 Year 10 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052032


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name